House Majority Leader Steve Scalise Diagnosed With Treatable Blood Cancer
House Majority Leader Steve Scalise has been diagnosed with a treatable form of blood cancer, known as multiple myeloma, CNBC reported. Scalise disclosed that he had started medical treatment after feeling unwell for some time. The treatment is expected to last several months. See Also: Trump’s…#stevescalise #trump #capitol #laborday #alexandria #virginia #yousolar (Source: Reuters: Health)
Source: Reuters: Health - August 30, 2023 Category: Consumer Health News Source Type: news
The family torn apart by cancer: Father, 53, who lost all THREE of his children to brain tumors and leukemia dies from disease - leaving behind his wife
Regis Feitosa Mota, 53,[left] from Fortaleza had battled off cancer three times since 2016. But in January this year he was diagnosed with the blood cancer multiple myeloma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2023 Category: Consumer Health News Source Type: news
FDA Provides Accelerated Approval of Talvey for Multiple Myeloma
TUESDAY, Aug. 15, 2023 -- The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
The accelerated approval is for individuals who have received at least four prior... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2023 Category: General Medicine Source Type: news
New Bispecific Antibody Nabs Conditional FDA Approval for Myeloma
(MedPage Today) -- The FDA granted accelerated approval to the bispecific antibody elranatamab (Elrexfio) for relapsed/refractory multiple myeloma treated with at least four prior regimens.
A B-cell maturation antigen (BCMA)-directed T-cell engager... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 15, 2023 Category: American Health Source Type: news
FDA Approves Elranatamab for Multiple Myeloma FDA Approves Elranatamab for Multiple Myeloma
Elranatamab is an off-the-shelf, B-cell maturation antigen CD3-targeted bispecific antibody.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Pfizer's ELREXFIO ™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
(Source: Reuters: Health)
Source: Reuters: Health - August 14, 2023 Category: Consumer Health News Source Type: news
FDA Grants Accelerated Approval for Elrexfio (elranatamab-bcmm) for Relapsed or Refractory Multiple Myeloma
The approval of Elrexfio (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study
Elrexfio is the first off-the-shelf (ready-to-use) fixed-dose subcutaneous BCMA-directed agent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 14, 2023 Category: Drugs & Pharmacology Source Type: news
Pfizer & #039;s ELREXFIO ™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Source: World Pharma News)
Source: World Pharma News - August 14, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
‘Major step forward’ for adult patients as new blood cancer drug receives FDA approval
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Talvey, a new antibody-based therapy for adult patients with tough-to-treat such as multiple myeloma. The drug is made by Johnson & Johnson. This is a "major step forward" for the myeloma field, according to Dr. Ola…#fda #talvey #johnsonjohnson #olalandgren #phd #myelomaprogram #foxnewsdigital #newaitechaimsto #landgren #myeloma (Source: Reuters: Health)
Source: Reuters: Health - August 12, 2023 Category: Consumer Health News Source Type: news
FDA OKs Talquetamab, a First-in-Class Multiple Myeloma Drug FDA OKs Talquetamab, a First-in-Class Multiple Myeloma Drug
The approval follows a series of market withdrawals for other multiple myeloma drugs that initially received accelerated FDA approval.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Talvey (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
HORSHAM, Pa., Aug. 10, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Talvey™ (talquetamab-tgvs), a first-in-class... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 10, 2023 Category: Drugs & Pharmacology Source Type: news
First-in-Class Drug Approved for Heavily Pretreated Myeloma
(MedPage Today) -- The FDA granted accelerated approval to talquetamab (Talvey) for treating adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, drug developer Janssen announced Thursday... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 10, 2023 Category: Hematology Source Type: news
FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma
On August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 10, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Episode 5: CAR T-Cell Therapy for Multiple Myeloma Episode 5: CAR T-Cell Therapy for Multiple Myeloma
Join Drs Amelia Langston and Jonathan L. Kaufman, MD, as they discuss current CAR –T cell for B-cell lymphomas as leading researchers and practitioners in the field.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 10, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Radiomics algorithm finds key biomarker in multiple myeloma
In patients with multiple myeloma, an MRI radiomics machine-learning algorith...Read more on AuntMinnie.comRelated Reading:
PET/CT radiomics help with multiple myeloma prognosis
AI algorithm identifies multiple myeloma lesions on whole-body CT
Photon-counting CT + AI improves imaging of bone disease
SIIM: AI can detect multiple myeloma lesions on whole-body CT
PET/CT predicts treatment outcomes in myeloma patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 4, 2023 Category: Radiology Source Type: news
